Malta - English - Medicines Authority

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 10 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 10 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 20 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 40 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 80 mg - lipid modifying agents

Malta - English - Medicines Authority

hexal pharma gmbh stella-klein-low-weg 17, 1020 wein, austria - cilostazol - tablet - cilostazol 100 mg - antithrombotic agents

European Union - English - EMA (European Medicines Agency)

abz-pharma gmbh - filgrastim - neutropenia; hematopoietic stem cell transplantation; cancer - colony stimulating factors - biograstim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.biograstim is indicated for the mobilisation of peripheral blood progenitor cells (pbpc).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.biograstim is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloxetine - diabetic neuropathies - psychoanaleptics, - treatment of diabetic peripheral neuropathic pain in adults.

European Union - English - EMA (European Medicines Agency)

infai, institut für biomedizinische analytik nmr-imaging gmbh - urea (13c) - breath tests; helicobacter infections - diagnostic agents - helicobacter test infai may be used for in vivo diagnosis of gastroduodenal helicobacter pylori infection in:adults;adolescents, who are likely to have peptic ulcer disease.helicobacter test infai for children aged three to 11 years may be used for in vivo diagnosis of gastrduodenal helicobacter pylori infection:for the evaluation of the success of eradication treatment, or;when invasive tests cannot be performed, or;when there are discordant results arising from invasive tests.this medicinal product is for diagnostic use only.

European Union - English - EMA (European Medicines Agency)

bayer animal health gmbh  - pradofloxacin - antibacterials for systemic use, fluoroquinolones - dogs; cats - dogstreatment of:wound infections caused by susceptible strains of the staphylococcus intermedius group (including s. pseudintermedius);superficial and deep pyoderma caused by susceptible strains of the staphylococcus intermedius group (including s. pseudintermedius);acute urinary-tract infections caused by susceptible strains of escherichia coli and the staphylococcus intermedius group (including s. pseudintermedius);as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by susceptible strains of anaerobic organisms, for example porphyromonas spp. and prevotella spp.catstreatment of acute infections of the upper respiratory tract caused by susceptible strains of pasteurella multocida, escherichia coli and the staphylococcus intermedius group (including s. pseudintermedius).